In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.

In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.

INTRODUCTION: Trastuzumab, a humanized antibody directed against the Her2 receptor, induces the expression of p27(kip1), an intranuclear cyclin-dependent kinase inhibitor in some breast cancer cells. The aim of this study was to develop a radioimmunoconjugate (RIC) to monitor trastuzumab-induced p27...

書誌詳細
主要な著者:	Cornelissen, B, Kersemans, V, McLarty, K, Tran, L, Vallis, K, Reilly, R
フォーマット:	Journal article
言語:	English
出版事項:	2009

類似資料

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
著者:: Cornelissen, B, 等
出版事項: (2008)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
著者:: Cornelissen, B, 等
出版事項: (2009)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
著者:: McLarty, K, 等
出版事項: (2009)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
著者:: Costantini, D, 等
出版事項: (2008)

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
著者:: Costantini, D, 等
出版事項: (2010)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
著者:: Costantini, D, 等
出版事項: (2007)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
著者:: Caroline Chung, 等
出版事項: (2009-01-01)

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
著者:: McLarty, K, 等
出版事項: (2009)

Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
著者:: Caroline Muñoz, 等
出版事項: (2024-03-01)

Chemotherapy-induced cardiotoxic effect in breast cancer patients treated with trastuzumab (Herceptin) by MRI
著者:: Mohamed Aboulfotouh Mourad, 等
出版事項: (2023-12-01)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
著者:: Cornelissen, B, 等
出版事項: (2008)

Biodistribution and nuclear import of 111In-labeled HIV-1 tat peptide immunoconjugates after intravenous or intratumoural injection in tumour-bearing mice
著者:: Cornelissen, B, 等
出版事項: (2006)

The importance of antibody dependent cell-mediated cytotoxicity (ADCC) for breast cancer response to trastuzumab - Herceptin
著者:: Juranić Zorica D., 等
出版事項: (2002-01-01)

Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief
著者:: Mohammad Reza Rouhollahi, 等
出版事項: (2014-04-01)

Validation of ELISA Test-system for Trastuzumab (Herceptin, Hertikad) quantitative determination in biological fluids
著者:: V. V. Pisarev, 等
出版事項: (2023-05-01)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
著者:: Florence R. Wilson, 等
出版事項: (2018-11-01)

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
著者:: Brunet Joan, 等
出版事項: (2007-05-01)

Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells.
著者:: Cornelissen, B, 等
出版事項: (2007)

Kinetics of internalization and nuclear import and efflux of 111In-and 123I-labeled HIV-1 tat-peptide immunoconjugates (IC's) in BT-474 human breast cancer cells
著者:: Cornelissen, B, 等
出版事項: (2006)

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
著者:: Soudabeh Akbarzadeh-Sharbaf, 等
出版事項: (2012-01-01)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
著者:: Florence R. Wilson, 等
出版事項: (2017-10-01)

Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth.
著者:: Tatiana V Komarova, 等
出版事項: (2011-01-01)

Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
著者:: Yousif Nasser, 等
出版事項: (2011-10-01)

Prática de clínica dos enfermeiros portugueses: administração subcutânea de trastuzumab (herceptin®) e rituximab (mabthera®)
著者:: Alice Monteiro, 等
出版事項: (2018-06-01)

A preliminary study to establish the transfected CHO cell lines which highly express Trastuzumab - A biosimilar product of Herceptin
著者:: Nguyen Quang Huy, 等
出版事項: (2022-11-01)

A model system to explore the detection limits of antibody-based immuno-SPECT imaging of exclusively intranuclear epitopes
著者:: Veal, M, 等
出版事項: (2021)

Ultrasound-triggered herceptin liposomes for breast cancer therapy
著者:: Amal Elamir, 等
出版事項: (2021-04-01)

Effect of recombinant Herceptin on the growth of breast cancer cells
著者:: Nafiseh Kiarostami, 等
出版事項: (2019-06-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
著者:: Volkmar Müller, 等
出版事項: (2018-03-01)

Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability
著者:: Kong Sun-Young, 等
出版事項: (2008-10-01)

Herceptin resistance in HER2-moderately expressed breast cancer
著者:: Kerry, J, 等
出版事項: (2012)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
著者:: Costantini, D, 等
出版事項: (2010)

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.
著者:: Fredersdorf, S, 等
出版事項: (1997)

Cell penetrating peptides for in vivo molecular imaging applications.
著者:: Kersemans, V, 等
出版事項: (2008)

Regulation of p27<sup>Kip1</sup> and p57<sup>Kip2</sup> Functions by Natural Polyphenols
著者:: Gian Luigi Russo, 等
出版事項: (2020-09-01)

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial
著者:: Naveen Reddy, 等
出版事項: (2024-03-01)

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
著者:: Qing Chen, 等
出版事項: (2017-01-01)

Screening For Small Molecule Inhibitors Of p27Kip1 Degradation
著者:: Ooi, Li Ching
出版事項: (2012)

p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia
著者:: Hiroaki Komuro, 等
出版事項: (1999-08-01)

p27kip1 at the crossroad between actin and microtubule dynamics
著者:: Gian Luca Rampioni Vinciguerra, 等
出版事項: (2019-04-01)